<DOC>
	<DOCNO>NCT00922363</DOCNO>
	<brief_summary>The purpose study evaluate safety profile CAF01 , administer 50 µg Ag85B-ESAT-6 alone 50 µg Ag85B-ESAT-6 three escalate CAF01 dose level , four group healthy volunteer , inject two dos two month interval .</brief_summary>
	<brief_title>Trial Safety New Liposomal Adjuvant System , CAF01 , When Given With Tuberculosis Subunit Vaccine Ag85B-ESAT-6 Two Injections With Two Months Interval Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Female male adult 18 55 year age 2 . Healthy accord medical history medical examination screen 3 . Signed informed consent 4 . Prepared grant authorized person access medical record 5 . Likely comply instruction 1 . History tuberculosis know exposure tuberculosis ( expect ) clinical trial 2 . Positive Tuberculin Skin Test ( TST ) result screen 3 . Positive QuantiFERON® TB Gold InTube test result accord manufacturer 's specification screen 4 . BCG vaccination time enter trial 5 . History ongoing congenital acquire immune deficiency , autoimmune disease thyroid dysfunction 6 . Disease affect lymphoid organ ( Hodgkin 's disease , lymphoma , leukaemia , sarcoidosis ) 7 . ANATiter , HBV , HCV , HIV seropositive screen 8 . Creactive protein level &gt; 50 mg/L screen 9 . Clinically significant abnormal laboratory test result screen assessed investigator 10 . Severe ongoing viral bacterial infection might affect cell mediate immune response 11 . A condition repeat blood drawing pose minimal risk subject , haemophilia , coagulation disorder , significantly impaired venous access 12 . Live vaccine vaccination ( MMR , yellow fever , oral typhoid ) within 3 month first vaccination 13 . Immune modulate drug administration ( immunoglobulin , systemic corticosteroid , azathioprine , cyclosporine , infliximab , blood product vaccine ) within 3 month first vaccination 14 . Known hypersensitivity vaccine component investigational vaccine 15 . Intake another clinical trial product/vaccine within 3 month first vaccination participation previous clinical trial Ag85BESAT6 antigen 16 . Pregnant accord urine pregnancy test inclusion 17 . Females willing use contraceptive breast feed 18 . Has condition opinion investigator suitable participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>safety</keyword>
	<keyword>vaccine</keyword>
	<keyword>tuberculosis</keyword>
	<keyword>CAF01</keyword>
	<keyword>Ag85B-ESAT-6</keyword>
	<keyword>prevention</keyword>
</DOC>